Posted: 15 April 2024 Semaglutide is part of the glucagon-like peptide-1 (GLP-1) receptor targeting family of peptide drugs, which are mainly used to treat diabetes but are difficult and expensive to make. An international team of researchers led…
Posted: 11 April 2024 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health, is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study…
Posted: 11 April 2024 Patrys Limited a therapeutic antibody development company, is delighted to announce that new data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis were…
Posted: 11 April 2024 Amplia Therapeutics limited is pleased to provide an update on our Phase 1b/2a trial (the ACCENT trial) of narmafotinib in combination with standard-of-care chemotherapy gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer.…
Posted: 11 April 2024 Clarity Pharmaceuticals (ASX:CU6) (“Clarity” or “Company”) a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce a fully…
Posted: 11 April 2024 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University (“La Trobe”) are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke…
Posted: 11 April 2024 Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess…
Posted: 11 April 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP)…
Posted: 21 March 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has expanded its exosome intellectual property (IP) portfolio by filing an Australian Provisional Patent Application (APPA) covering its cutting-edge EXO-ACE technology for large…
Posted: 21 March 2024 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University (“La Trobe”) are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke in the…
Posted 20 March 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP)…
Posted: 15 March 2024 Researchers have found a new way to potentially treat one of the most common forms of acute lymphoblastic leukaemia. The study, led by WEHI and the Peter MacCallum Cancer Centre, was able to kill…